Analyses on AML cells harboring DNMT3A mutations revealed that despite global DNA hypomethylation specific regions of the genome are instead hypermethylated, also justifying the usage of HMAs in this context to restore normal methylation levels at these specific sites. This evidence concerns the gene DNMT3A and acute myeloid leukemia.